Understanding the Market | VISEN PHARMA-B rises nearly 4% again, Longpei Growth Promoter is expected to be approved for listing within the year, and the company continues to advance its commercialization process

VISEN PHARMA-B rose nearly 4% again, as of the time of writing, up 2.81%, priced at HKD 44.68. According to VISEN PHARMA's prospectus, the company's fastest research and development progress is in Longpei Growth Hormone (long-acting growth hormone), which is expected to be approved for domestic listing in the second half of 2025, potentially becoming the third long-acting growth hormone to be listed in China. Currently, the company has two unique products, namely Nepeptin and Parotipratide, with the latter expected to submit a listing application by the end of 2025. It is reported that in June this year, VISEN PHARMA reached a cooperation agreement with WuXi Biologics to promote localized production, striving to meet the clinical needs of domestic patients with cost-effective high-value products. In July this year, VISEN also partnered with Anke Bio to jointly promote the commercialization of products, and the future market prospects are worth looking forward to